Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 17

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 17
---
 Cara Board recommends that the holders of Cara common stock vote:

#### •

“

#### FOR
” Proposal 1 — the Stock Issuance Proposal;

#### •

“

#### FOR
” Proposal 2 — the Equity Plan Proposal;

#### •

“

#### FOR
” Proposal 3 — the ESPP Proposal;

#### •

“

#### FOR
” Proposal 4 — the Reverse Stock Split Proposal;

#### •

“

#### FOR
” Proposal 5 — the Authorized Share Proposal;

#### •

“

#### FOR
” Proposal 6 — the Compensation Proposal; and

#### •

“

#### FOR
” Proposal 7 — the Adjournment Proposal.

For more information on each proposal and the Cara Board’s recommendations, please see the section titled “ Matters Being Submitted to a Vote of Cara’s Stockholders ” beginning on page 217of this proxy statement/prospectus.

**Q:

How many votes are needed to approve each Cara Proposal?

A:

Approval of each of the Stock Issuance Proposal, the Equity Plan Proposal, the ESPP Proposal, the Reverse Stock Split Proposal and the Authorized Share Proposal requires the affirmative vote from a majority of the votes cast by the holders of shares present at the meeting (by virtual attendance) or represented by proxy. Approval of the Compensation Proposal and the Adjournment Proposal requires votes from the majority of shares present in person (by virtual attendance) or represented by proxy at the meeting and entitled to vote on the matter.

Q:

What risks should I consider in deciding whether to vote in favor of the Cara Proposals?

A:

You should carefully review the section titled “ Risk Factors ,” beginning on page 27of this proxy statement/prospectus.

Q:**

#### When do you expect the Merger to be consummated?
A:

We anticipate that the Merger will be consummated during the first half of 2025, soon after the Cara special meeting to be held on April 1, 2025, but we cannot predict the exact timing. For more information, please see the section titled “ The Merger Agreement — Conditions to the Completion of the Merger ” beginning on page 195of this proxy statement/prospectus.

Q:

What are the material U.S. Federal Income Tax consequences of the Merger to holders of Cara common stock?

A:

Cara stockholders will not sell, exchange or dispose of any shares of Cara common stock as a result of the Merger. Thus, there will be no material U.S. federal income tax